NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-CA-22-069 from the NIH Guide for Grants and Contracts
Notice NOT-AT-22-004 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-104 from the NIH Guide for Grants and Contracts
Notice NOT-MH-22-201 from the NIH Guide for Grants and Contracts
Notice NOT-MH-22-200 from the NIH Guide for Grants and Contracts
Notice NOT-HD-22-002 from the NIH Guide for Grants and Contracts
Notice NOT-TR-22-028 from the NIH Guide for Grants and Contracts
Notice NOT-GM-22-030 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-103 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-102 from the NIH Guide for Grants and Contracts
Notice NOT-GM-22-032 from the NIH Guide for Grants and Contracts
Notice NOT-TR-22-027 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-23-021 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research projects, directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and stimulant use disorders (StUD). Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics; and (2) medical therapeutic and diagnostic devices, including software as a medical device. This FOA strives to contribute to the effort against national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis.
Notice NOT-OD-22-099 from the NIH Guide for Grants and Contracts
Notice NOT-MH-22-170 from the NIH Guide for Grants and Contracts
Notice NOT-DA-22-052 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-092 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-22-013 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to establish a PDXNet Data Commons and Coordinating Center (PDCCC). PDCCC will interact with and coordinate with the PDX (Patient-Derived Xenograft) Development and Trial Centers Research Network (PDXNet) comprised of five PDX Development and Trial Centers (PDTCs, to be supported by companion FOA, RFA-CA-22-012) in a collaborative network. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale development and pre-clinical testing of targeted therapeutic agents in patient-derived models to advance the vision of cancer precision medicine. The goals for PDTCs include development of preclinical data in PDX models to translate into clinical trials; the strategic development of new PDX models to fill public resource gaps; and development of new methods and metrics for preclinical in vivo testing of single agents and drug combinations. The PDCCC will serve as the coordinating and data analysis center of the PDXNet. It is expected that the outcomes of PDXNet research will be particularly important for the prioritization of combinations of agents in the portfolio of NCI Investigational New Drugs (NCI-IND agents), which are evaluated clinically in the NCIs Experimental Therapeutic Clinical Trials Network (ETCTN). PDXNet will encompass up to five PDTCs (to be supported by a companion FOA, RFA-CA-22-012) and a single PDCCC (to be supported by this FOA). PDXNet will be supported by the NCI Patient-Derived Models Repository (PDMR) at the Frederick National Laboratory for Cancer Research (FNLCR). PDTCs and the PDCCC will be expected to collaborate with PDMR in several areas related to the goals of the program, including the development of optimized standardized procedures, and in sharing PDX models.
Funding Opportunity RFA-CA-22-012 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) requests applications for PDX (patient-derived xenografts) Development and Trial Centers (PDTCs) to serve as the laboratory research units of the PDX Development and Trial Centers Research Network (PDXNet). The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale development and pre-clinical testing of targeted therapeutic agents in patient-derived models (PDMs) to advance the vision of cancer precision medicine. The main goals for PDTCs include: develop and implement mechanism-based preclinical trials of drug combinations in large sets of molecularly characterized PDXs to advance cancer precision medicine through the therapeutic development of these agents, with a focus on NCI-IND agents; provide evidence-based recommendations for early phase clinical trials to be conducted in NCI clinical trial networks by identifying agent combinations that produce in vivo evidence of deep and durable responses of PDX models to the therapeutic intervention; develop and characterize new PDX models to share with the NCI Patient Derived Models Repository (PDMR) that fill identified resource gaps in the PDMR collection. This includes PDX models from patients with clinical drug resistance, models obtained from racial/ethnic minority populations, and models of rare cancers; engage collaboratively as a network to develop and apply metrics for preclinical in vivo drug response that improves the value of PDX drug response data in predicting clinical outcomes; advance the understanding of therapeutic outcome disparities by race/ethnicity to ensure that early phase clinical trials are well equipped to support diverse and equitable recruitment; and devise procedures and platforms to make preclinical PDX data broadly available to researchers across the cancer community, using PDTCs and NCI mutually agreed upon standards.
Notice NOT-HG-22-006 from the NIH Guide for Grants and Contracts